or Try an Advanced Search...

    Technical Analysis for EQ - Equillium, Inc.

    Grade Last Price % Change Price Change
    D 0.83 -3.60% -0.03
    EQ closed down 3.6 percent on Friday, November 1, 2024, on 1.64 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical EQ trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    Hammer Candlestick Bullish 0.00%
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Fell Below 20 DMA Bearish -3.60%
    Fell Below 200 DMA Bearish -3.60%
    Fell Below 50 DMA Bearish -3.60%
    New Downtrend Bearish -3.60%
    Stochastic Sell Signal Bearish -3.60%
    Expansion Pivot Sell Setup Bearish Swing Setup -3.60%
    Older End-of-Day Signals for EQ ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 21 hours ago
    Up 1% about 21 hours ago
    Down 10% about 23 hours ago
    2x Volume Pace about 23 hours ago
    3x Volume Pace about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    EQ Chart by TradingView
    Basic chart:

    Profile

    Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders

    Is EQ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Equillium says Ono not acquiring itolizumab, stock craters 36%
    Oct 31 Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
    Oct 31 Equillium Maintains Rights to Itolizumab Following Ono Partnership
    Oct 31 Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
    Oct 22 Alto Ingredients And 2 Other US Penny Stocks To Watch Closely
    Oct 7 Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
    Sep 17 Equillium collaborates with Vivtex for oral formulation of autoimmune therapy
    Sep 10 Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
    Aug 28 Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
    Aug 11 Equillium Second Quarter 2024 Earnings: Beats Expectations
    See more EQ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.25
    52 Week Low 0.45
    Average Volume 189,828
    200-Day Moving Average 1.32
    50-Day Moving Average 0.97
    20-Day Moving Average 1.06
    10-Day Moving Average 1.15
    Average True Range 0.14
    RSI (14) 40.12
    ADX 37.26
    +DI 23.92
    -DI 32.38
    Chandelier Exit (Long, 3 ATRs) 1.07
    Chandelier Exit (Short, 3 ATRs) 1.18
    Upper Bollinger Bands 1.40
    Lower Bollinger Band 0.71
    Percent B (%b) 0.18
    BandWidth 65.94
    MACD Line 0.05
    MACD Signal Line 0.07
    MACD Histogram -0.0216
    Fundamentals Value
    Market Cap 29.15 Million
    Num Shares 35.1 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -3.77
    Price-to-Sales 1.27
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.02
    Resistance 3 (R3) 1.02 0.95 0.99
    Resistance 2 (R2) 0.95 0.90 0.95 0.98
    Resistance 1 (R1) 0.89 0.87 0.86 0.89 0.97
    Pivot Point 0.82 0.82 0.80 0.82 0.82
    Support 1 (S1) 0.76 0.77 0.73 0.77 0.69
    Support 2 (S2) 0.69 0.74 0.70 0.68
    Support 3 (S3) 0.63 0.69 0.67
    Support 4 (S4) 0.64